Report
Valens Research

ESRX - Embedded Expectations Analysis - 2018 08 03

Express Scripts Holding Company (ESRX:USA) is currently trading near recent lows relative to UAFRS-based (Uniform) Earnings, with a 10.6x Uniform P/E. At these levels, the market has bearish expectations for the firm, driven by the loss of Anthem, potential limitations on legal protection for drug rebates and uncertainty regarding the approval of the Cigna merger

Specifically, the market appears concerned about the loss of the firm's relationship with Anthem after 2020, which accounted for $19bn in sales in 2017. Additionally, the market may be concerned about potential regulations that would limit the legal protection of drug price rebates among PBM (Pharmacy-benefit managers). Finally, the market may lack confidence in their ability to get the proposed merger between ESRX and Cigna Corp. (CI:USA) approved
Underlying
Express Scripts Holding Company

Express Scripts Holding is a pharmacy benefit management (PBM) company. The company has two reportable segments: PBM, which consists of clinical solutions, Express Scripts SafeGuardRx

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch